News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abiogen Pharma And Oryx Pharmaceuticals Inc. : A License Agreement For Disodium Clodronate


10/19/2005 5:09:13 PM

PISA, Italy--(BUSINESS WIRE)--June 20, 2005--The license agreement grants Oryx the exclusive license to market the speciality Clasteon (R) (the bisphosphonate Disodium Clodronate) in Canada. Oryx Pharmaceutical Inc. launched Clasteon (R) 400 mg capsules in May 2004 and currently purchases the finished product from Abiogen which manufactures it at its new facility located in the industrial area of Pisa.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES